A targeted, low-throughput compound screen in a<i>Drosophila</i>model of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD)
bioRxiv (Cold Spring Harbor Laboratory)